Abstract
Summary: The established impact of gut microbiota-and probiotic-derived metabolites on immune-checkpoint blockade (ICB) has spurred extensive efforts to identify strains and druggable bioactive molecules of microbial origin that can improve tumor immune therapy. In this issue, Kawanabe-Matsuda and colleagues show that the exopolysaccharide EPS-R1 produced by the probiotic strain Lactobacillus delbrueckii subsp. bulgaricus augments the response to ICB therapy by expanding the population of Peyer’s patches CCR6+ CD8+ T cells, which can subsequently migrate from the gut into CCL20-expressing tumors to enhance antitumor activity.
Original language | English |
---|---|
Pages (from-to) | 1189-1190 |
Number of pages | 2 |
Journal | Cancer discovery |
Volume | 12 |
Issue number | 5 |
DOIs | |
State | Published - May 1 2022 |